FDA Approval Granted On New Titanium Dental Implant

Double-Strength Metal Expected To Integrate Into Bone Up To 20 Times Faster $2 Billion Dental-Implant Market Is Goal

December 9, 2008

Click here to view the printer friendly version of this press release

 

Manhattan Scientifics (Pink Sheets:MHTX) today announced that its affiliated manufacturing partner in Albuquerque, N.M. has received Food and Drug Administration 510(k) clearance to market Manhattan Scientifics’ super strong titanium metal dental implants. This clearance positions the company closer to its goal of commercializing its technology and increasing shareholder value.

The patented new form of titanium metal originally developed by Russian scientists in concert with scientists at the Los Alamos National Laboratory is expected to significantly improve dental implants. Studies have shown that bone integrates with these new metals up to 20 times faster than with conventional metals. Patients should experience shorter post surgery healing times and a more reliable integration of these new implants into their body.

Manhattan Scientifics Chief Scientist Terry Lowe said, "The $2 billion annual dental implant wholesale market is 10% the size of the market for other medical devices (for example hips, spinal devices and cardiovascular stents) that can benefit from the advantages of our advanced metals."

The key manufacturers of dental implants include Nobel Biocare Holding AG (SWX:NOBN), Straumann Holding AG (SWX:STMN), Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH), DENTSPLY International, Inc. (NasdaqGS: XRAY), Biomet, Inc. and Thommen Medical AG.

Manhattan Scientifics anticipates developing additional products based on this new titanium metal for use in orthopedics and stents.

U.S. Food and Drug Administration - 510(k) Premarket Notification Database

About Manhattan Scientifics

Manhattan Scientifics, Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Forward-looking statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.